313P A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression

The prevalence of MET overexpression in NSCLC varied from 5%-75% and it may be concurrent with MET amplification. Several studies demonstrated that MET overexpression was an independent worse prognostic factor among EGFR wild-type NSCLC patients and may be a potential therapeutic target in NSCLC patients. SCC244, a highly selective and potent oral MET TKI, demonstrated high efficacy and acceptable safety profile in NSCLC patients with MET exon 14 skipping mutation. The purpose of the analysis was to evaluate the efficacy of SCC244 in MET overexpression NSCLC patients.